VeraSci will be attending CTAD 2020, on November 4-7. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for Alzheimer’s Disease, to predict progression, and assess the effectiveness of new treatments. Dr. Alex Atkins will be presenting the poster:

Real-time capture of gait and actigraphy using industry-grade wearable devices in older adults with and without subjective cognitive decline: Preliminary compliance, sensitivity, and correlations with cognition